Cantor Fitzgerald Reiterates Neutral on CVS Health, Maintains $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on CVS Health and maintained a $58 price target.
June 12, 2024 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on CVS Health and maintained a $58 price target.
The reiteration of a Neutral rating and maintenance of the $58 price target suggests that the analyst does not foresee significant short-term changes in CVS Health's stock price. This is likely to result in a neutral impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100